

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brett Anthony Mitchell
Date of last notice	9 March 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Brett and Michelle Mitchell <Mitchell Spring Family A/C> Trustee Brett and Michelle Mitchell <Lefthanders Super Fund A/C> Trustee
Date of change	9 September 2021
No. of securities held prior to change	<p>Brett and Michelle Mitchell <Mitchell Spring Family A/C> 22,264,444 Fully Paid Ordinary Shares 2,500,000 Performance Rights 277,777 Listed Options exercisable at \$0.045 each expiring 31 August 2021</p> <p>Brett and Michelle Mitchell <Lefthanders Super Fund A/C> 8,140,560 Fully Paid Ordinary Shares 2,500,000 Performance Rights 277,777 Listed Options exercisable at \$0.045 each expiring 31 August 2021</p> <p>Chieftain Securities (WA) Pty Ltd 5,000,000 Unlisted Options exercisable at \$0.15 expiring 30 June 2021 1,500,000 Unlisted Options exercisable at \$0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.07 expiring 31 August 2023</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	<ol style="list-style-type: none"> 1. Performance Rights Class A expiring 1 April 2025 2. Performance Rights Class B expiring 1 April 2025 3. Performance Rights Class C expiring 30 June 2024 4. Listed Options expiring 31 August 2021 5. Fully Paid Ordinary Shares 6. Options expiring 30 June 2021
Number acquired	<p>Brett and Michelle Mitchell <Mitchell Spring Family A/C></p> <ol style="list-style-type: none"> 2. 17,500,000 Performance Rights Class B expiring 1 April 2025 5. 277,777 Fully Paid Ordinary Shares <p>Brett and Michelle Mitchell <Lefthanders Super Fund A/C></p> <ol style="list-style-type: none"> 1. 7,500,000 Performance Rights Class A expiring 1 April 2025 3. 2,400,000 Performance Rights Class C expiring 30 June 2024 5. 277,777 Fully Paid Ordinary Shares
Number disposed	<p>Brett and Michelle Mitchell <Mitchell Spring Family A/C>:</p> <ol style="list-style-type: none"> 5. 277,777 Unlisted options (exercised) <p>Brett and Michelle Mitchell <Lefthanders Super Fund A/C>:</p> <ol style="list-style-type: none"> 5. 277,777 Unlisted options (exercised) <p>Chieftain Securities (WA) Pty Ltd</p> <ol style="list-style-type: none"> 6. 5,000,000 Unlisted Options exercisable at \$0.15 expiring 30 June 2021
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<p>Brett and Michelle Mitchell <Mitchell Spring Family A/C>:</p> <ol style="list-style-type: none"> 2. Nil – Grant of Incentive Performance Rights 5. \$12,499.96 on exercise of 277,777 Unlisted options <p>Brett and Michelle Mitchell <Lefthanders Super Fund A/C>:</p> <ol style="list-style-type: none"> 1. Nil – Grant of Incentive Performance Rights 3. Nil – Grant of Incentive Performance Rights 5. \$12,499.96 on exercise of 277,777 Unlisted options <p>6. Chieftain Securities (WA) Pty Ltd Nil, expiry of options</p>
No. of securities held after change	<p>Brett and Michelle Mitchell <Mitchell Spring Family A/C></p> <ol style="list-style-type: none"> 22,542,221 Fully Paid Ordinary Shares 2,500,000 Performance Rights 17,500,000 Performance Rights Class B expiring 1 April 2025 <p>Brett and Michelle Mitchell <Lefthanders Super Fund A/C></p> <ol style="list-style-type: none"> 8,418,337 Fully Paid Ordinary Shares 2,500,000 Performance Rights 7,500,000 Performance Rights Class A expiring 1 April 2025 2,400,000 Performance Rights Class C expiring 30 June 2024 <p>Chieftain Securities (WA) Pty Ltd</p> <ol style="list-style-type: none"> 1,500,000 Unlisted Options exercisable at \$0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.07 expiring 31 August 2023
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ol style="list-style-type: none"> 1.- 3. Grant of incentive Performance Rights 4.- 5. Exercise of Listed Options 6. Lapse of unexercised options

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Evan Hayes
Date of last notice	4 September 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	9 September 2021
No. of securities held prior to change	Nil
Class	1. Performance Rights Class A expiring 1 April 2025 2. Performance Rights Class B expiring 1 April 2025 3. Performance Rights Class C expiring 30 June 2024
Number acquired	1. 600,000 2. 1,400,000 3. 600,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – Granted Incentive Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	600,000 Performance Rights Class A expiring 1 April 2025 1,400,000 Performance Rights Class B expiring 1 April 2025 600,000 Performance Rights Class C expiring 30 June 2024
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of securities under employee incentive plan

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Nativ Segev
Date of last notice	11 February 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Bright Global Limited (Director and sole shareholder) HSBC Custody Nominees (Australia) Limited (Beneficiary)
Date of change	9 September 2021
No. of securities held prior to change	Direct: 1 Fully Paid Ordinary Share Bright Global Limited: 500,000 Fully Paid Ordinary Shares HSBC Custody Nominee (Australia) Limited: 52,500,000 Fully Paid Ordinary Shares
Class	1. Performance Rights Class A expiring 1 April 2025 2. Performance Rights Class B expiring 1 April 2025 3. Performance Rights Class C expiring 30 June 2024
Number acquired	1. 450,000 2. 1,050,000 3. 600,000
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – Granted Incentive Performance Rights
No. of securities held after change	Direct: 1 Fully Paid Ordinary Share Bright Global Limited: 500,000 Fully Paid Ordinary Shares 450,000 Performance Rights Class A expiring 1 April 2025 1,050,000 Performance Rights Class B expiring 1 April 2025 600,000 Performance Rights Class C expiring 30 June 2024 HSBC Custody Nominee (Australia) Limited: 52,500,000 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of securities under employee incentive plan

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ross Grant Thomas Walker
Date of last notice	15 July 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ross G T Walker Pty Ltd
Date of change	9 September 2021
No. of securities held prior to change	Ross G T Walker Pty Ltd: 4,370,370 Fully paid ordinary shares 185,185 Listed options expiring 31 August 2021
Class	1. Performance Rights expiring 1 April 2025 2. Performance Rights expiring 1 April 2025 3. Performance Rights expiring 30 June 2024 4. Listed options expiring 31 August 2021
Number acquired	1. 450,000 2. 1,050,000 3. 600,000
Number disposed	4. 185,185
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1. Nil – Granted Incentive Performance Rights 2. Nil – Granted Incentive Performance Rights 3. Nil – Granted Incentive Performance Rights 4. Nil – Lapsed Options

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	Ross G T Walker Pty Ltd: 4,370,370 Fully paid ordinary shares 450,000 Performance Rights expiring 1 April 2025 1,050,000 Performance Rights expiring 1 April 2025 600,000 Performance Rights expiring 30 June 2024
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1. Grant of securities under employee incentive plan 2. Grant of securities under employee incentive plan 3. Grant of securities under employee incentive plan 4. Lapsed Options

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Roby Reuven Zomer
Date of last notice	9 March 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Chitta Lu Limited (Director and sole shareholder) & HSBC Custody Nominees (Australia) Limited
Date of change	9 September 2021
No. of securities held prior to change	Chitta Lu Limited 3,000,001 Fully Paid Ordinary Shares 5,000,000 Performance Rights HSBC Custody Nominees (Australia) Limited 30,000,000 Fully Paid Ordinary Shares
Class	1. Performance Rights expiring 1 April 2025 2. Performance Rights expiring 1 April 2025 3. Performance Rights expiring 30 June 2024
Number acquired	1. 7,500,000 2. 17,500,000 3. 2,400,000

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – Granted Incentive Performance Rights.
No. of securities held after change	Chitta Lu Limited 3,000,001 Fully Paid Ordinary Shares 5,000,000 Performance Rights 7,500,000 Performance Rights Class A expiring 1 April 2025 17,500,000 Performance Rights Class B expiring 1 April 2025 2,400,000 Performance Rights Class C expiring 30 June 2024 HSBC Custody Nominees (Australia) Limited 30,000,000 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of securities under employee incentive plan

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stephen Barry Parker
Date of last notice	9 March 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1. Held through a UK Individual Savings Account ("ISA") Registered Holder is Barclays Bank PLC
Date of change	9 September 2021
No. of securities held prior to change	1. 282,316 Fully Paid Ordinary Shares
Class	1. Performance Rights Class A expiring 1 April 2025 2. Performance Rights Class B expiring 1 April 2025 3. Performance Rights Class C expiring 30 June 2024
Number acquired	1. 600,000 2. 1,400,000 3. 600,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – Granted Incentive Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	<p>1. Indirectly held through a UK Individual Savings Account ("ISA") Registered Holder is Barclays Bank PLC: 282,316 Fully Paid Ordinary Shares</p> <p>2. Directly Held: 600,000 Performance Rights Class A expiring 1 April 2025 1,400,000 Performance Rights Class B expiring 1 April 2025 600,000 Performance Rights Class C expiring 30 June 2024</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of incentive securities

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

*Rule 3.19A.2
Rule 3.19A.2*

+ See chapter 19 for defined terms.